A Chinese medicine composition for treating diabetic neurovascular coupling injury and its preparation method and use
Through the traditional Chinese medicine compositions Astragalus, Rehmannia, Salt Cuscuta, Powdered Kerma, Chicken Blood Vine, Salvia miltiorrhiza, Poria saccharomycea and Jingyuanzhi, combined with traditional Chinese medicine syndrome differentiation and typing, the treatment problem of diabetic neurovascular coupling injury is solved, and the symptoms and signs are significantly improved. An efficient and safe treatment plan is created.
Patent Information
- Application Number
- CN202411283511.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-09-13
AI Technical Summary
The prior art lacks dialectical typing and special Chinese patent medicine treatment for diabetic neurovascular coupling injury, resulting in poor treatment effect and insufficient improvement of neurovascular function.
A Chinese medicine composition is proposed, including Astragalus, Rehmannia, Salt Cuscuta, Powdered Kerma, Chicken Blood Vine, Salvia miltiorrhiza, Poria and Jingyuanzhi, according to the Chinese medicine syndrome classification standards (kidney deficiency and blood stasis syndrome, phlegm and turbidity blocking syndrome, liver and kidney Prepare into a pharmaceutical preparation for the treatment of diabetic neurovascular coupling injury.
It significantly improves the clinical symptoms and signs of diabetic neurovascular coupling injury and improves the quality of life of patients. Compared with traditional drugs, it has the advantages of small dosage, easy use, high bioavailability, no toxic side effects, and simple production process.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to a traditional Chinese medicine composition for treating diabetic neurovascular coupling injury and a preparation method and application thereof, belonging to the field of traditional Chinese medicine. Background Art
[0002] Diabetic neurovascular coupling injury is one of the common complications in diabetic patients, involving nerves, blood vessels and the interaction between them. This injury is usually related to the chronic hyperglycemia state of diabetes and can lead to a variety of clinical manifestations, including but not limited to pain, paresthesia, autonomic dysfunction, etc. Types of diabetic neuropathy include distal symmetrical polyneuropathy (DSPN), autonomic neuropathy, mononeuropathy, nerve root or plexus lesions, etc. Among them, DSPN is the most common type, manifested as symmetrical polysensory neuropathy, usually affecting the distal lower limbs first, which may be asymptomatic or manifested as pain and paresthesia.
[0003] Treatment of diabetic neurovascular coupling injury usually requires comprehensive management, including blood sugar control, pathogenesis treatment, symptom relief, and lifestyle improvement. Specific treatment methods may include the use of nerve nutrition drugs (such as methylcobalamin), antioxidant stress drugs (such as α-lipoic acid), drugs that inhibit aldose reductase activity (such as epalrestat), drugs that improve microcirculation, drugs that improve cellular energy metabolism, and traditional Chinese medicine treatment.
[0004] The treatment of diabetic neurovascular coupling injury with traditional Chinese medicine needs to be combined with the dialectical classification of traditional Chinese medicine. The current traditional Chinese medicine classification mainly focuses on the symptoms of diabetic neurovascular coupling injury, such as diabetic peripheral neuropathy (Li Xingquan, Changchun University of Chinese Medicine, Master's thesis June 2023). From the analysis of the pathological mechanism of Western medicine, diabetic peripheral neuropathy (DPN) is a common complication of diabetic patients, mainly manifested by symptoms such as limb numbness and pain. The lesions mainly affect the distal limbs and are symmetrical. Diabetic neurovascular coupling injury involves damage to the neurovascular unit (NVU), which is a functional unit composed of neurons, glial cells, vascular endothelial cells, etc., which interact to maintain the normal function of the tissue; diabetic peripheral neuropathy DPN mainly affects the peripheral nerves, while diabetic neurovascular coupling injury may affect the entire NVU, including retinal neuropathy; in terms of treatment, the treatment of DPN usually focuses on controlling blood sugar and relieving symptoms, such as the use of anti-epileptic drugs, antidepressants and opioids to relieve pain, while the treatment of diabetic neurovascular coupling injury may need to focus more on improving the function of the NVU, including the use of drug intervention, improving vascular health and possible neuroprotection strategies.
[0005] At present, there is no research on the TCM dialectical classification of diabetic neurovascular coupling injury, and there is no targeted Chinese patent medicine to treat diabetic neurovascular coupling injury. Summary of the invention
[0006] The present invention is based on the inventor's many years of clinical practice experience. First, a new set of TCM syndrome differentiation standards is proposed for diabetic neurovascular coupling injury. Based on this standard, the present invention provides a Chinese medicine composition for treating diabetic neurovascular coupling injury, as well as its preparation method and use.
[0007] The present invention provides a traditional Chinese medicine composition for treating diabetic neurovascular coupling injury, which is prepared from the following raw materials in weight ratio:
[0008] 24-36 parts of Astragalus, 8-12 parts of Rehmannia glutinosa, 16-24 parts of Cuscuta australis, 16-24 parts of Pueraria lobata, 24-36 parts of Millettia reticulata, 16-24 parts of Salvia miltiorrhiza, 12-18 parts of Poria cocos, and 12-18 parts of processed Polygala tenuifolia.
[0009] More preferably, it is prepared from the following bulk drugs in the following weight ratio:
[0010] 30 parts of Astragalus, 10 parts of Rehmannia glutinosa, 20 parts of Cuscuta australis, 20 parts of Pueraria lobata, 30 parts of Millettia reticulata, 20 parts of Salvia miltiorrhiza, 15 parts of Poria cocos, and 15 parts of processed Polygala tenuifolia.
[0011] The Chinese medicine composition of the present invention is prepared from the raw powder of the raw medicine, water or organic solvent extract as active ingredients, and pharmaceutically acceptable excipients or auxiliary ingredients to form a commonly used pharmaceutical preparation.
[0012] Wherein, the preparation is oral liquid, granules, capsules, and pills.
[0013] The present invention also provides a method for preparing the Chinese medicine composition for treating diabetic neurovascular coupling injury, which comprises the following steps:
[0014] a. Weigh the APIs of various weight ratios;
[0015] b. Powdering or extracting with water or organic solvent, adding pharmaceutically acceptable excipients or auxiliary ingredients to prepare into pharmaceutical preparations commonly used.
[0016] The present invention provides use of the traditional Chinese medicine composition in preparing a medicine for treating diabetic neurovascular coupling injury.
[0017] Wherein, the medicine is a medicine for treating diabetic neurovascular coupling injury of kidney deficiency and blood stasis syndrome type.
[0018] Wherein, the medicine is a medicine for treating diabetic retinopathy, diabetic peripheral neuropathy, and diabetic cognitive dysfunction.
[0019] Based on many years of clinical experience and combined with clinical dialectics of traditional Chinese medicine, the inventors have divided the syndrome differentiation of diabetic neurovascular coupling injury into the following three types: kidney deficiency and blood stasis syndrome, phlegm and turbidity blocking the collaterals syndrome, and liver and kidney yin deficiency syndrome.
[0020] Kidney deficiency and blood stasis syndrome: Symptoms include blurred vision, obstructed vision, dry eyes, numbness of limbs, insomnia and forgetfulness, soreness of waist and knees; accompanied by dizziness, tinnitus, fatigue, dull complexion, limb pain, paresthesia, frequent urination at night; pale purple tongue or with ecchymosis, thin white fur, and thready and wiry pulse. Treatment should be to tonify the kidney and replenish qi, and activate blood circulation and dredge collaterals.
[0021] Phlegm and turbidity blocking the collaterals: Symptoms include blurred vision, numbness of limbs, insomnia and forgetfulness, coughing up sputum, heavy limbs, mental depression, uncomfortable bowel movements, chest tightness and poor appetite, etc. The tongue is swollen with teeth marks, the tongue coating is white and greasy, and the pulse is slippery. The treatment should be to remove phlegm and turbidity, disperse blood stasis and dredge the collaterals.
[0022] Liver and kidney yin deficiency syndrome: symptoms include decreased vision, dry eyes, numbness of limbs, insomnia and forgetfulness, dizziness and tinnitus, dull pain in the flank, soreness of waist and knees, fever in the five parts of the body, spermatorrhea, spermatorrhea, or menstrual disorders, etc., red tongue with little coating, and weak and rapid pulse. Treatment should be to nourish the liver and kidney.
[0023] The disease of diabetes is caused by internal Yin deficiency, which first affects the lungs and spleen, and then damages the kidneys over time. As diabetes progresses, the disease enters the collaterals, and the disease progresses from blood stasis. Kidney deficiency and blood stasis lead to the occurrence of diabetic retinopathy; as diabetes progresses, the disease progresses to the kidneys, and kidney deficiency, blood stasis, and cold stagnation in the tendons and veins lead to diabetic peripheral neuropathy; as diabetes progresses, kidney essence is insufficient, and the essence cannot be transformed into qi, resulting in qi deficiency and blood stasis, and the brain marrow is malnourished, leading to diabetic cognitive dysfunction. Therefore, kidney deficiency and blood stasis coexist in the process of diabetic retinopathy, diabetic peripheral neuropathy, and diabetic cognitive dysfunction. Kidney deficiency must be accompanied by blood stasis, and blood stasis aggravates kidney deficiency. Kidney deficiency is the root cause, and blood stasis is the symptom. Blood stasis leads to the generation of new pathogenic factors, aggravating kidney deficiency from many aspects. "Kidney deficiency and blood stasis" is the common pathogenesis and key symptom of diabetic retinopathy, diabetic peripheral neuropathy, and diabetic cognitive dysfunction.
[0024] The Chinese medicine composition of the present invention is mainly used to treat the syndrome of kidney deficiency and blood stasis, and is composed of astragalus, Rehmannia glutinosa, salt dodder seed, kudzu root, Millettia spatholobi, salvia miltiorrhiza, poria, and processed polygala. In the raw material formula, astragalus is the main drug, which tastes sweet and slightly warm, nourishes qi and blood, relieves stagnation and relieves numbness to resolve blood stasis. Rehmannia glutinosa is the ministerial drug, which tastes sweet, warm and moisturizing, nourishes yin and tonifies the kidney, replenishes essence and replenishes marrow; salt dodder seed nourishes the liver and kidney and improves eyesight, and both drugs belong to the liver and kidney meridians, dredge blood vessels, nourish yin and improve eyesight. Pueraria lobata, Millettia spatholobi, salvia miltiorrhiza, poria wood, and processed polygala are adjuvant drugs, Pueraria lobata promotes body fluid and quenches thirst, promotes menstruation and activates collaterals, Millettia spatholobi activates blood circulation and regulates menstruation, relaxes tendons and activates collaterals, salvia miltiorrhiza activates blood circulation, removes blood stasis and relieves pain, and the three drugs play the effects of promoting blood circulation, dredge collaterals and removes blood stasis, and dredges the Xuanfu; Poria wood calms the mind and calms the nerves, and Polygala spatholobi calms the mind and improves intelligence, and communicates the heart and kidney, and the two drugs play the effects of calming the mind and improving intelligence. The combination of these medicines can nourish the kidney and replenish qi, promote blood circulation and dredge meridians.
[0025] The drug of the present invention is indicated for: kidney deficiency and blood stasis syndrome of diabetic neurovascular coupling damage (diabetic retinopathy, diabetic peripheral neuropathy, diabetic cognitive dysfunction), clinical manifestations of which are: blurred vision, dry eyes, limb numbness, insomnia and forgetfulness, soreness of waist and knees, dizziness and tinnitus, mental fatigue, fatigue, dark complexion, limb pain, paresthesia, frequent urination at night, etc., pale purple tongue with ecchymosis, and sluggish pulse.
[0026] The beneficial effects of the present invention are:
[0027] The present invention establishes the TCM diagnosis and treatment standard for diabetic neurovascular coupling injury, and the Chinese medicine composition of the present invention treats diabetic neurovascular coupling injury as a whole. Compared with methylcobalamin tablets and ginkgo leaf tablets, the Chinese medicine granules of the present invention have the advantages of small dosage, convenient use, high bioavailability, no toxic side effects, stable quality, and simple production process. DETAILED DESCRIPTION
[0028] Example 1 Preparation of the drug of the present invention
[0029] Weigh the bulk drug in the weight ratio:
[0030] Astragalus 30g, Rehmannia glutinosa 10g, Salt Cuscuta chinensis 20g, Pueraria lobata 20g, Millettia reticulata 30g, Salvia miltiorrhiza 20g, Poria 15g, Processed Polygala tenuifolia 15g.
[0031] Add 8 times the amount of water to the above eight medicinal materials, soak for 30 minutes, heat and extract for 1 hour, filter, and collect the filtrate; add 8 times the amount of water to the residue, boil for 1 hour, filter, and combine the two filtrates; reduce the pressure on the filtrate to concentrate it to a relative density of about 1.15 (60°C), add an appropriate amount of dextrin, granulate it using a fluidized bed, and dry it to obtain the product.
[0032] Example 2 Preparation of the drug of the present invention
[0033] Weigh the bulk drug in the weight ratio:
[0034] Astragalus 24g, Rehmannia glutinosa 8g, Cuscuta australis 16g, Pueraria lobata 16g, Millettia reticulata 24g, Salvia miltiorrhiza 16g, Poria cocos 12g, Polygala tenuifolia 12g. Prepare according to the method of Example 1.
[0035] Example 3 Preparation of the drug of the present invention
[0036] Weigh the bulk drug in the weight ratio:
[0037] Astragalus 36g, Rehmannia glutinosa 12g, Cuscuta australis 24g, Pueraria lobata 24g, Millettia reticulata 36g, Salvia miltiorrhiza 24g, Poria 18g, Polygala tenuifolia 18g. Prepare according to the method of Example 1.
[0038] The beneficial effects of the present invention are demonstrated by clinical trials as follows.
[0039] Test Example 1 Clinical trial of the drug of the present invention
[0040] The Chinese medicine of the present invention has been clinically tested in several hospitals in Sichuan Province, and the clinical test results are summarized as follows:
[0041] 1. Case selection
[0042] The clinical trial of the Chinese medicine of the present invention treated 77 patients with diabetic neurovascular coupling injury, including 42 cases in the experimental group and 35 cases in the control group. The clinical symptoms, signs, laboratory tests and imaging examinations of the treated patients were all consistent with the diagnosis of diabetic neurovascular coupling injury.
[0043] 2. Diagnostic criteria
[0044] (1) Diabetes
[0045] The diagnosis of diabetes mellitus was based on the 1999 WHO criteria.
[0046] (2) Diabetic neurovascular coupling injury
[0047] ①OCT examination showed that the thickness of the retinal nerve fiber layer (RNFL) in the upper quadrant was <144.0 μm;
[0048] ②OCTA examination showed that the area of the foveal avascular zone (FAZ) was > 0.30 mm 2 ;
[0049] ③CCM showed corneal nerve fiber length (CNFL) <17.0mm / mm 2 ;
[0050] ④fMRI cortical and subcortical brain atrophy, gray matter (GM) volume <500cm 3 .
[0051] ⑤ The peak time of P100 of 10 spatial frequencies observed by VEP examination is >110ms;
[0052] ⑥ERG detection a wave amplitude (uV) <200uV, b wave amplitude (uV) <400uV;
[0053] ⑦ Montreal Cognitive Assessment (MoCA) score: score <26 points (if the number of years of education is ≤12 years, the score needs to be increased by 1 point);
[0054] ⑧ Mini-Mental State Examination (MMSE) score <27 points;
[0055] ⑨Toronto Clinical Scoring System (TCSS) score>5 points.
[0056] If the above 4 items are met, or 2 items from ①-④ + 2 items from ⑤-⑨ are met, diabetic neurovascular coupling injury can be diagnosed.
[0057] (3) Diabetic retinopathy
[0058] The diagnosis of diabetic retinopathy refers to the diabetic retinopathy grading standard established by the International Society of Ophthalmology in 2002, as shown in Table 1:
[0059] Table 1 International clinical grading standards for diabetic retinopathy (2002 edition)
[0060]
[0061] (4) Diabetic peripheral neuropathy
[0062] Distal symmetric polyneuropathy (DSPN) is the most representative form of diabetic peripheral neuropathy. The diagnostic criteria for DSPN refer to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)", including:
[0063] ① Clear history of diabetes;
[0064] ②Neuropathy that occurs at or after the diagnosis of diabetes;
[0065] ③Clinical symptoms and signs are consistent with those of DSPN;
[0066] ④ Exclude the following situations: Especially when the disease progresses rapidly, the lesion site is asymmetric, and the motor function damage is significantly more severe than the sensory function damage, it is necessary to exclude other causes of neuropathy, such as cervical and lumbar spine lesions (nerve root compression, spinal stenosis, cervical and lumbar degeneration), cerebral infarction, Guillain-Barré syndrome; severe arteriovenous vascular lesions (venous thrombosis, lymphangitis), etc.; vitamin B12 deficiency; infection (such as human immunodeficiency virus, etc.); neurotoxic effects caused by drugs, especially chemotherapy drugs, and damage to the nerves caused by metabolic toxins caused by renal insufficiency.
[0067] (5) Cognitive dysfunction in diabetes
[0068] According to the severity of the disease, diabetic cognitive dysfunction is mainly divided into cognitive decline, mild cognitive impairment (MCI) and dementia. The diagnosis of MCI refers to the MCI diagnostic procedure established by the European Alzheimer's Disease (AD) Association in 2011:
[0069] ① Main complaint: memory loss.
[0070] ②The total score of Montreal Cognitive Assessment (MoCA) is <26 points.
[0071] ③ Overall cognitive function is fully preserved, with a total score of at least 24 points on the Mini-Mental State Examination (MMSE).
[0072] ④ Maintaining intact daily living activities or with only very mild impairment, with a total score of the Daily Living Activity Scale (ADL) <26 points.
[0073] Those who meet all four of the above criteria are considered to have MCI.
[0074] (6) TCM syndrome differentiation standards
[0075] The diagnostic criteria for kidney deficiency and blood stasis syndrome were formulated with reference to the "Diagnosis and Efficacy Standards for Chinese Medicine Diseases and Syndromes" and the "Principles for Clinical Research Indicators for New Chinese Medicines (Trial Version)" (see attachment).
[0076] Main symptoms: blurred vision, blocked vision, dry eyes, numbness of limbs, insomnia and forgetfulness, soreness of waist and knees;
[0077] Secondary symptoms: dizziness, tinnitus, mental fatigue, fatigue, dull complexion, limb pain, paresthesia, frequent urination at night, etc.;
[0078] Tongue and pulse: The tongue is pale purple or has ecchymosis, the tongue coating is thin white, and the pulse is thready and wiry.
[0079] The diagnosis can be confirmed by combining 2 of the above main symptoms and 3 of the secondary symptoms with tongue and pulse.
[0080] 3. Inclusion criteria
[0081] (1) According to the 1999 WHO standard, meet the diagnostic criteria for diabetes;
[0082] (2) According to the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition) and the MCI diagnostic procedure developed by the European Alzheimer's Disease (AD) Association in 2011, the patient meets one of the following three disease diagnoses: ① diabetic retinopathy, graded as non-proliferative mild or moderate (at least one eye meets the criteria); ② DSPN (distal symmetric polyneuropathy); ③ diabetes mellitus combined with cognitive impairment, with the disease stage being MCI (mild cognitive impairment);
[0083] (3) TCM diagnosis of kidney deficiency and blood stasis;
[0084] (4) Glycated hemoglobin ≤ 9%;
[0085] (5) Aged 18-70, regardless of gender;
[0086] (6) The patient signs the informed consent form.
[0087] 4. Exclusion criteria
[0088] (1) Retinopathy caused by other causes (such as retinal vein occlusion, age-related macular degeneration, etc.), peripheral neuropathy (such as cervical and lumbar spine disease, Guillain-Barré syndrome, vitamin B12 deficiency, etc.) and cognitive dysfunction (such as endocrine and metabolic dysfunction, sleep disorders, etc.);
[0089] (2) Patients with acute complications of diabetes (diabetic ketoacidosis, diabetic nonketotic hyperosmolar syndrome, etc.) and severe chronic complications (such as diabetic nephropathy with nephrotic syndrome, diabetic lower limb artery occlusion, etc.);
[0090] (3) Patients with severe dysfunction of heart, liver, kidney, etc. or autoimmune diseases;
[0091] (4) Those who have mental illness, intellectual disability, etc. and are unable to cooperate with the study;
[0092] (5) Those with allergies or known to be allergic to or intolerant of the drugs used in this study;
[0093] (6) Participated in or is currently participating in other trials within the past 3 months;
[0094] (7) Women who are preparing for pregnancy, pregnant or breastfeeding;
[0095] 5. Observation indicators
[0096] 5.1 Evaluation criteria for therapeutic efficacy of diabetic neurovascular coupling injury
[0097] Representative biological indicators that are simple to measure and easy to calculate were selected from the evaluation indicators of diabetic neurovascular coupling injury: retinal nerve fiber layer thickness (RNFL), Montreal Cognitive Assessment (MoCA) score, Mini-Mental State Examination (MMSE) score; and tests were performed before and after treatment.
[0098] 5.2 Evaluation criteria for TCM symptom efficacy
[0099] With reference to the 2002 edition of the “Guidelines for Clinical Research of New Chinese Medicines”, the evaluation criteria for TCM symptom efficacy were formulated:
[0100] (1) Significant effect: Clinical symptoms and signs disappear or almost disappear, and the symptom score decreases by ≥95%:
[0101] (2) Effective: Clinical symptoms and signs are significantly improved, and the symptom score is reduced by ≥70%; Effective: Clinical symptoms and signs are improved, and the symptom score is reduced by ≥30%:
[0102] (3) Ineffective: There is no significant improvement or aggravation of clinical symptoms and signs, and the symptom score decreases by <30%.
[0103] Note: Therapeutic effect index (n) = [(score before treatment - score after treatment) / score before treatment] × 100%
[0104] 5.3 Safety indicators:
[0105] Systemic reactions; routine blood and urine tests; electrocardiogram, liver and kidney function tests; closely observe the subjects' systemic conditions during medication, paying attention to any adverse reactions. If any suspected heart, liver or kidney lesions or corresponding symptoms occur, conduct safety tests at any time.
[0106] 6. Drug usage and precautions
[0107] How to use the drug:
[0108] The experimental group took 10g granules (equivalent to 26.6g of the original medicinal materials) of the present invention (astragalus, Rehmannia root, salt dodder seed, Pueraria root, Millettia reticulata, Salvia miltiorrhiza, Poria, and processed Polygala tenuifolia) with boiled water, three times a day, for 8 weeks;
[0109] The control group was given basic treatment and nerve nutrition treatment (gingko leaf tablets (2 tablets each time, three times a day), methylcobalamin capsule (1 tablet each time, three times a day)) for 8 weeks.
[0110] Notes during use:
[0111] Strictly observe adverse events during treatment and take necessary measures to provide treatment. Observe the manifestation, severity, time of occurrence, duration and outcome of adverse events to determine the relationship between adverse events and the drug of the present invention.
[0112] 7. Statistical analysis
[0113] SPSS23.0 was used for statistical analysis. Mean and standard deviation (continuous variables that followed normal distribution), median and quartile (continuous variables that did not follow normal distribution), and frequency and percentage (categorical variables) were used for statistical description. Continuous variables were compared between groups using t-test or Mann-Whitney U test, and categorical variables were compared between groups using Pearson chi-square test or Fisher's exact test. P < 0.05 was considered statistically significant.
[0114] 8. Results
[0115] 8.1 General Information
[0116] The clinical trial of the Chinese medicine of the present invention treated 77 patients with diabetic neurovascular coupling injury, including 42 cases in the experimental group, 22 females and 20 males, aged 35 to 68 years old, with an average age of (49.45±6.61) years old; the course of disease was 5 months to 23 years, with an average age of (6.17±2.33) years; the control group had 35 cases, 18 females and 17 males, aged 36 to 62 years old, with an average age of (51.23±5.89) years old; the course of disease was 8 months to 20 years, with an average age of (6.32±3.18) years; there was no significant difference in the general data of the two groups of patients, P>0.05, the two groups were comparable, and the experiment was feasible (see Table 2).
[0117] Table 2 Comparison of general information of the two groups of patients
[0118] material Experimental group (n=42) Control group (n=35) P Age (years) (49.45±6.61) (51.23±5.89) 0.526 Gender (female / male) 52.4% / 47.6% 51.4% / 48.6% 0.956 Disease duration (years) (6.17±2.33) (6.32±3.18) 0.840
[0119] 8.2 Evaluation of therapeutic efficacy of diabetic neurovascular coupling injury (see Table 3)
[0120] Table 3 Comparison of therapeutic effects of diabetic neurovascular coupling injury between the two groups
[0121]
[0122] Among them, the t value, whose full name is t-statistic, is mainly used to measure the difference between the sample mean and the overall mean (or between two sample means); the p value, also known as the significance value or Sig value, is used to describe the probability of observing current data or more extreme data under the premise that the original hypothesis is true.
[0123] The results are shown in Table 3. There were no significant differences in retinal nerve fiber layer thickness (RNFL), Montreal Cognitive Assessment (MoCA) scores, and Mini-Mental State Examination (MMSE) scores between the experimental group and the control group before treatment. After treatment, all values of the experimental group were significantly higher than those of the control group (P < 0.05), and there were significant differences between the two groups.
[0124] 8.3 Evaluation of TCM Symptom Efficacy (see Table 4)
[0125] Table 4 Comparison of TCM symptom efficacy between the two groups of patients
[0126] Group Number of cases Clinically effective Clinically effective Clinically ineffective Total Effectiveness Experimental Group 42 5 cases (11.9%) 32 cases (76.1%) 5 cases (11.9%) 37 cases (88.0%) Control group 35 2 cases (5.7%) 17 cases (48.5%) 16 cases (45.7%) 19 cases (54.3%)
[0127] The clinical marked efficacy, clinical efficacy and total efficacy of the experimental group were significantly higher than those of the control group (P<0.05).
[0128] 8.4 Safety indicators:
[0129] No adverse events were observed in both groups during the observation period.
[0130] Appendix: Diagnosis and treatment criteria for diabetic neurovascular coupling injury
[0131] 1 Definition
[0132] Neurovascular coupling (NVC) is an instantaneous change in which neural activity induces a rapid increase in local blood flow to meet local brain energy needs. Neurovascular coupling disorder in the early stages of diabetes will lead to a series of tissue and organ functional injuries, namely diabetic neurovascular coupling injury, mainly including diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN), and diabetic cognitive impairment (MCI).
[0133] 2 Etiology and pathogenesis
[0134] Diabetic neurovascular coupling injury belongs to the category of complications of "Xiao Ke" in traditional Chinese medicine. The etiology is believed to be related to the congenital weakness of the five internal organs, insufficient endowment, acquired fatigue, excessive fatigue, unhealthy diet, and old age. The disease mainly involves the liver, spleen, and kidney. In terms of pathogenesis, neurovascular coupling injury is believed to be caused by long-term thirst, which affects the kidneys for a long time, resulting in insufficient kidney essence, kidney deficiency and blood stasis, stagnation of eye meridians, lack of nourishment to the brain, and obstruction of tendons and veins.
[0135] 3 Clinical manifestations
[0136] 3.1 Symptoms
[0137] Diabetic neurovascular coupling injury occurs in the early stages of diabetes and has an insidious onset. There may be no obvious clinical manifestations at the beginning of the disease. As the disease progresses, mild neurovascular damage may occur, and double vision, decreased vision, blurred vision, delayed reaction, paresthesia, and numbness of the feet may occur. As the damage worsens, floaters appear in the eyes, vision is significantly reduced or even blind, numbness, pain, and ants appear in the limbs, and the brain shows symptoms such as slowed cognitive speed, prolonged reaction time, decreased short-term memory capacity, and severe loss of time and space sense.
[0138] 3.2 Physical signs
[0139] Retinal microaneurysms, hemorrhagic spots, hard exudates, cotton wool spots, etc. may appear in the eyes, cognitive and motor dysfunction of the central nervous system, as well as muscular atrophy and weakness of the peripheral nervous system, and weakened or disappeared Achilles tendon reflex and knee reflex.
[0140] 4Symptoms
[0141] Traditional Chinese medicine does not have a specific disease name for diabetic neurovascular coupling injury, and the clinical manifestations are variable, and there is no unified standard for syndrome differentiation. The following syndrome differentiation must meet the three main symptoms plus the four secondary symptoms (excluding tongue and pulse) to make a diagnosis.
[0142] 4.1 Kidney deficiency and blood stasis type
[0143] Main symptoms: blurred vision, blocked vision, dry eyes, numbness of limbs, insomnia and forgetfulness, soreness of waist and knees;
[0144] Secondary symptoms: dizziness, tinnitus, mental fatigue, fatigue, dull complexion, limb pain, paresthesia, frequent urination at night, etc.;
[0145] Tongue and pulse: The tongue is pale purple with ecchymosis and the pulse is sluggish.
[0146] 4.2 Phlegm and turbidity blocking the collaterals
[0147] Main symptoms: blurred vision, numbness of limbs, insomnia, forgetfulness, coughing and spitting phlegm;
[0148] Secondary symptoms: heaviness of limbs, mental depression, uncomfortable bowel movements, chest tightness, poor appetite, fatigue, irritability, etc.
[0149] Tongue and pulse: The tongue is fat with teeth marks, the tongue coating is white and greasy, and the pulse is slippery.
[0150] 4.3 Liver and Kidney Yin Deficiency
[0151] Main symptoms: decreased vision, dry eyes, numbness of limbs, insomnia and forgetfulness, dizziness and tinnitus, dull pain in the flank, soreness in the waist and knees, and fever in the five parts of the body;
[0152] Secondary symptoms: insomnia, dreaminess, dry mouth and throat, spermatorrhea and spermatorrhea in men, menstrual disorders in women, red cheeks, night sweats, dizziness, etc.
[0153] Tongue and pulse: red tongue with little coating, fine and rapid pulse.
[0154] 5 Diagnostic criteria
[0155] (1) Diabetes: Diagnosis is based on the 1999 WHO criteria, as follows:
[0156]
[0157] Note: OGTT is an oral glucose tolerance test; HbA1c is glycosylated hemoglobin. Typical symptoms of diabetes include polydipsia, polyuria, polyphagia, and unexplained weight loss; random blood sugar refers to blood sugar at any time of the day regardless of the last meal time, and cannot be used to diagnose impaired fasting glucose or impaired glucose tolerance; fasting state refers to no food intake for at least 8 hours.
[0158] (2) Symptoms: double vision, decreased vision, blurred vision, delayed reaction, paresthesia, numbness of the feet; eye floaters, significant decreased vision or even blindness, numbness, pain, and crawling sensation in the limbs; slowed cognitive speed, prolonged reaction time, decreased short-term memory capacity, and severe loss of sense of time and space.
[0159] (3) Physical signs: retinal microaneurysms, hemorrhagic spots, hard exudates, cotton wool spots, etc., cognitive and motor dysfunction of the central nervous system, muscle atrophy and weakness of the peripheral nervous system, and weakened or absent Achilles tendon reflex and knee reflex.
[0160] (4) Multimodal imaging examination of the eye and brain: ①OCT examination showed that the thickness of the retinal nerve fiber layer (RNFL) in the upper quadrant was <144.0 μm; ②OCTA examination showed that the area of the foveal avascular zone (FAZ) was >0.30 mm 2 ; ③CCM showed corneal nerve fiber length (CNFL) <17.0mm / mm 2 ④fMRI cortical and subcortical brain atrophy, gray matter (GM) volume <500cm 3 ⑤VEP inspection observation 1 0 The peak time of spatial frequency P100 is >110ms; ⑥ERG detection a wave amplitude (uV) <200uV, b wave amplitude (uV) <400uV; ⑦Montreal Cognitive Assessment (MoCA) score: score <26 points (if the years of education ≤ 12 years, the score needs to be added by 1 point); ⑧Mini-Mental State Examination (MMSE) score <27 points; ⑨Toronto Clinical Scoring System (TCSS) score >5 points.
[0161] If the above 4 items are met, or 2 items among ①-④ + 2 items among ⑤-⑨ are met, diabetic neurovascular coupling injury can be diagnosed.
[0162] 6 Western medicine classification standards
[0163]
[0164] 7 Treatment
[0165] 7.1 Basic intervention
[0166] The basic intervention for diabetic neurovascular coupling injury includes early psychological care, exercise intervention, and dietary guidance. For example, early intervention can be carried out through psychological awareness guidance for diabetic neurovascular coupling injury, appropriate exercise, diabetic diet, and hypoglycemic drugs to control blood sugar levels, thereby reducing the incidence rate, reducing patient suffering, and reducing the patient's disability rate.
[0167] 7.2 Syndrome differentiation and treatment
[0168] 7.2.1 Kidney deficiency and blood stasis type
[0169] Clinical manifestations: blurred vision, dry eyes, numbness of limbs, insomnia and forgetfulness, soreness of waist and knees, dizziness and tinnitus, mental fatigue, fatigue, dull complexion, limb pain, abnormal sensation, frequent urination at night, etc., pale purple tongue with ecchymosis, and sluggish pulse.
[0170] Treatment principle: Nourish the kidney and replenish qi, promote blood circulation and dredge meridians.
[0171] 7.2.2 Phlegm and turbidity blocking the collaterals
[0172] Clinical manifestations: blurred vision, numbness of limbs, insomnia, forgetfulness, coughing and spitting saliva, heavy limbs, mental depression, uncomfortable bowel movements, chest tightness and poor appetite, etc. The tongue is fat and has teeth marks, the tongue coating is white and greasy, and the pulse is slippery.
[0173] Treatment principle: Clear away phlegm, resolve turbidity, disperse blood stasis and dredge meridians.
[0174] 7.2.3 Liver and Kidney Yin Deficiency
[0175] Clinical manifestations: decreased vision, dry eyes, numbness of limbs, insomnia, forgetfulness, dizziness and tinnitus, dull pain in the flank, soreness of waist and knees, fever in the five parts of the body, spermatorrhea, spermatorrhea, or menstrual disorders, etc., red tongue with little coating, and thin and rapid pulse.
[0176] Treatment principle: Nourish the liver and kidneys.
[0177] 7.3 Preventive care
[0178] Nutritional diet treatment, self-monitoring and diabetes education for diabetes are important means to prevent diabetic neurovascular coupling damage. Nutritional diet chooses a diet with a low glycemic index to keep the blood sugar curve flat. Self-monitoring and diabetes education refer to helping patients build confidence and self-monitoring, which is crucial to stabilizing blood sugar and is an important prerequisite for preventing diabetic neurovascular coupling damage.
[0179] 8.4 Evaluation criteria for efficacy
[0180] 8.4.1 Evaluation criteria for therapeutic efficacy of diabetic neurovascular coupling injury
[0181] According to the Diagnosis and Treatment Standards for Diabetic Neurovascular Coupling Injury, the efficacy evaluation is as follows:
[0182] (1) Significant effect: The disease grade is reduced by 2 grades or more, which is considered as marked effect;
[0183] (2) Effective: The disease grade is reduced by one level and is considered effective;
[0184] (3) Stable: The disease classification is stable and no change is considered stable.
[0185] (4) Ineffective: If the disease grade increases by 1 level or more, it is judged as ineffective.
[0186] 8.4.2 Statistical analysis was performed on the RNFL, CNFL, FAZ area, GM volume, VEP, ERG, MoCA score, MMSE score, and TCSS score of the two groups before and after treatment (self-control before and after treatment, and between-group control) to evaluate the clinical efficacy.
[0187] 8.4.3 TCM Symptom Therapy Evaluation Criteria
[0188] With reference to the 2002 edition of the “Guidelines for Clinical Research of New Chinese Medicines”, the evaluation criteria for TCM symptom efficacy were formulated:
[0189] (1) Recovery: Clinical symptoms and signs disappear or almost disappear, and symptom score decreases by ≥95%:
[0190] (2) Markedly effective: clinical symptoms and signs are significantly improved, with symptom scores reduced by ≥70%; Effective: clinical symptoms and signs are improved, with symptom scores reduced by ≥30%:
[0191] (3) Ineffective: There is no significant improvement or aggravation of clinical symptoms and signs, and the symptom score decreases by <30%.
[0192] Note: Therapeutic effect index (n) = [(score before treatment - score after treatment) / score before treatment] × 100%
[0193] Symbols and abbreviations:
[0194] NVC – Neurovascular Coupling
[0195] DR – diabetic retinopathy
[0196] DPN – diabetic peripheral neuropathy
[0197] MCI - Diabetic Cognitive Impairment
[0198] OCT - Optical Coherence Tomography
[0199] OCTA - Optical Coherence Tomography Vascular Imaging
[0200] CCM - Corneal Confocal Microscopy
[0201] fMRI — functional magnetic resonance imaging
[0202] VEP - visual evoked potential
[0203] ERG – Electroretinogram
[0204] MoCA - Montreal Cognitive Assessment
[0205] MMSE - Mini-Mental State Examination
[0206] TCSS – Toronto Clinical Scoring System
[0207] RNFL - retinal nerve fiber layer
[0208] FAZ - foveal avascular zone
[0209] CNFL - corneal nerve fiber length
[0210] GMV - Gray Matter Volume
Claims
1. A Chinese medicine composition for treating diabetic neurovascular coupling injury, characterized in that: It is prepared from the following raw materials in the following weight ratio: 24-36 parts of Astragalus, 8-12 parts of Rehmannia glutinosa, 16-24 parts of Cuscuta australis, 16-24 parts of Pueraria lobata, 24-36 parts of Millettia reticulata, 16-24 parts of Salvia miltiorrhiza, 12-18 parts of Poria cocos, and 12-18 parts of processed Polygala tenuifolia.
2. The Chinese medicine composition for treating diabetic neurovascular coupling injury according to claim 1, characterized in that: It is prepared from the following raw materials in the following weight ratio: 30 parts of Astragalus, 10 parts of Rehmannia glutinosa, 20 parts of Cuscuta australis, 20 parts of Pueraria lobata, 30 parts of Millettia reticulata, 20 parts of Salvia miltiorrhiza, 15 parts of Poria cocos, and 15 parts of processed Polygala tenuifolia.
3. The Chinese medicine composition for treating diabetic neurovascular coupling injury according to claim 1 or 2, characterized in that: The raw drug powder or water or organic solvent extract of the raw drug is used as the active ingredient, and pharmaceutically acceptable auxiliary materials or auxiliary ingredients are added to prepare a commonly used pharmaceutical preparation.
4. The Chinese medicine composition for treating diabetic neurovascular coupling injury according to claim 3, characterized in that: The preparation is oral liquid, granules, capsules and pills.
5. A method for preparing the Chinese medicine composition for treating diabetic neurovascular coupling injury according to any one of claims 1 to 4, characterized in that: It includes the following steps: a. Weigh the APIs of various weight ratios; b. Powdering or extracting with water or organic solvent, adding pharmaceutically acceptable excipients or auxiliary ingredients to prepare into pharmaceutical preparations commonly used.
6. Use of the Chinese medicine composition according to claim 1 in the preparation of a drug for treating diabetic retinopathy of kidney deficiency and blood stasis syndrome, diabetic distal symmetrical polyneuropathy, and diabetes combined with mild cognitive impairment.
